Akebia Therapeutics

Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with kidney disease. They primarily generate revenue through the sale of their FDA-approved drug, Auryxia, and through partnerships and collaborations for their pipeline products. Founded in 2007, Akebia has a significant history of mergers and acquisitions, including the notable merger with Keryx Biopharmaceuticals in 2018, which expanded their product portfolio and market reach.

Recent Posts by Akebia Therapeutics

1-20 of 100